GlobalData on MSN2d
Nammi Therapeutics doses first subject in trial of QXL138AM for multiple myeloma
Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating ...
Pharmabiz2d
Nammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myeloma
Nammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myeloma: Los Angeles Monday, November 11, 2024, 13:00 Hrs [IST] Nammi ...
The Victoria Advocate6d
Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma
LOS ANGELES, Nov. 8, 2024 /PRNewswire/ -- Nammi Therapeutics ... solid tumor indications with high CD138 prevalence and multiple myeloma) with primary endpoints focused on safety and tolerability ...
BioSpace7d
Gilead, Arcellx Tout Best-in-Class Potential for CAR T Therapy in Multiple Myeloma
Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...
The Globe and Mail16d
Refractory Multiple Myeloma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Currently it is in Phase III stage of clinical trial evaluation to treat Refractory Multiple Myeloma. RAPA-201: Rapa Therapeutics RAPA-201 It is a type of autologous cell therapy. The drug ...
Medscape3d
Multiple Myeloma and Hyperammonemic Encephalopathy: Review of 27 Cases
Previous reports of HE in the course of MM up to April 2008 were identified using a MEDLINE (National Library of Medicine, Bethesda, MD) search with the subject heads "multiple myeloma ...
Medscape2d
Kyphoplasty for Patients With Multiple Myeloma is a Safe Surgical Procedure: Results From a Large Patient Cohort
The data of 76 patients with 190 kyphoplasty-treated vertebrae were analyzed retrospectively (Figure 3). In our collective, the standard postoperative CT of the kyphoplasty-treated vertebrae ...
Medindia6d
Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma
LOS ANGELES, Nov. 8, 2024 /PRNewswire/ -- Nammi Therapeutics, Inc. (Nammi), a clinical stage ... cohorts (two solid tumor indications with high CD138 prevalence and multiple myeloma) with primary ...